As of early 2026, only 13 state Medicaid programs cover GLP-1 medications for weight loss, down from 17 states at the start of the year California, New Hampshire, Pennsylvania, and South Carolina dropped coverage on January 1, 2026, citing budgetary constraints from the high cost of medications like Ozempic, Wegovy, and Zepbound
2.6 (Hamamatsu Photonics, Shizuoka, Japan)
By simultaneously activating the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, it effectively promotes insulin secretion and reduces glucagon release, leading to better blood sugar regulation and weight loss support
High), and individuals with T2DM (Class IIIII
Ketone testing is recommended during illness, regardless of blood glucose levels